Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dEGF4KDEL
- Development stage
- Preclinical
- Lead developer
- University of Minnesota
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
**dEGF4KDEL** is an investigational, single-chain deimmunized bispecific ligand-directed toxin developed at the University of Minnesota. It fuses human epidermal growth factor and interleukin-4 targeting ligands to a truncated, deimmunized *Pseudomonas aeruginosa* exotoxin A payload with a C-terminal KDEL retention sequence. The molecule binds epidermal growth factor receptor and interleukin-4 receptor-positive tumor cells, is internalized, and delivers the exotoxin catalytic domain to inhibit protein synthesis and induce cell death. It showed preclinical antitumor activity in pancreatic cancer xenograft models, including inhibition of orthotopic MIA PaCa-2 tumors and metastasis, and related publications describe activity in breast cancer and malignant mesothelioma models. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22258068/))
- Other names
- dEGF4KDELdEGF-4KDELdEGF 4KDELdeimmunized EGF4KDELEGF4KDEL 7mutEGF-4KDEL 7mutEGF 4KDEL 7mut
02
Targets
EGFR (Epidermal growth factor receptor)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on dEGF4KDEL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dEGF4KDEL.